Journal of Developmental Medicine(Electronic Version)  2020, Vol. 8 Issue (1): 47-52 DOI: 10.3969/j.issn.2095-5340.2020.01.009 |
|
|
|
|
|
|
| Clinical analysis of budesonide intervention in the treatment of severe neonatal acute respiratory distress syndrome |
| YIN Xiao-juan, ZHANG Xuan, CHEN Jia,et al
|
| 1. Pediatrics, Hainan Hospital of PLA Genenal Hospital, Hainan 100191, China;2. Neonatal Intensive Care Unit of Bayi Children's Hospital, Seventh Medical Center of PLA General Hospital, Beijing 100700, China |
|
|
|
Abstract 【Abstract】 Objective To investigate the therapeutic effect of budesonide on severe neonatal acute respiratory distress syndrome (NARDS). Methods In the neonatal intensive care unit (NICU) of Bayi Children's Hospital, Seventh Medical Center of PLA General Hospital, 70 cases with severe NARDS were recruited from December 31, 2017 to November 30, 2019 and randomly divided into two groups, 35 cases in the intervention group and 35 cases in the control group. In the intervention group, budesonide was used with intratracheal instillation, 0.5 mg/kg per time, once per 8 hours, for 2 days; the control group was
given the same volume of saline in the same way. Perinatal pregnancy maternal, neonatal clinical data andblood gas analysis indicators of the two groups were collected and analyzed. The statistical analysis was carried out by t test, χ2 test or Fisher's exact test. Results There was no significant difference in perinatal maternal data between the two groups (P>0.05). The ratio of HFOV used in the intervention group (74.3%) was higher than that in the control group (51.4%) (χ2=3.916, P<0.05) , while the ratio of pulmonary surfactant used in the intervention group (45.7%) was lower than that in the control group (71.4%) (χ2=4.769,P<0.05) . The ratio of air leakage in the intervention group (2.9%) was lower than that in the control group
(20.0%) (P<0.05). The ratio of airway hyperresponsiveness (cough) in the intervention group (14.3%) was lower than that in the control group (48.6%) (χ2=9.545, P<0.05). There was no statistical significance in the length of hospitalization, death, and ECMO treatment between the two groups (all P>0.05); there was no statistical significance in the ratio of hypertension, edema, hypokalemia, and hypernatremia between the two groups (all P> 0.05). There was also no statistical significance in PaCO2, PaO2 and OI before and 7 days after treatment between the two groups (P>0.05). Conclusion Budesonide can reduce air leakage,
prevent or alleviate airway hyperresponsiveness, and has therapeutic effect on NARDS.
|
|
Received: 16 December 2019
Published: 22 January 2020
|
|
|
|
|
|
